Inhibrx Biosciences (INBX) Operating Margin (2023 - 2025)
Historic Operating Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Q2 2025 value amounting to 2106.85%.
- Inhibrx Biosciences' Operating Margin rose 1587911500.0% to 2106.85% in Q2 2025 from the same period last year, while for Sep 2025 it was 11949.57%, marking a year-over-year increase of 61676900.0%. This contributed to the annual value of 165724.0% for FY2024, which is 1535450600.0% down from last year.
- Per Inhibrx Biosciences' latest filing, its Operating Margin stood at 2106.85% for Q2 2025, which was up 1587911500.0% from 1595.43% recorded in Q1 2025.
- In the past 5 years, Inhibrx Biosciences' Operating Margin registered a high of 1595.43% during Q1 2025, and its lowest value of 160898.0% during Q2 2024.
- Over the past 3 years, Inhibrx Biosciences' median Operating Margin value was 21956.66% (recorded in 2023), while the average stood at 49017.42%.
- Its Operating Margin has fluctuated over the past 5 years, first tumbled by -445247600bps in 2024, then surged by 1587911500bps in 2025.
- Over the past 3 years, Inhibrx Biosciences' Operating Margin (Quarter) stood at 5403.24% in 2023, then tumbled by -824bps to 49928.0% in 2024, then surged by 96bps to 2106.85% in 2025.
- Its Operating Margin was 2106.85% in Q2 2025, compared to 1595.43% in Q1 2025 and 49928.0% in Q4 2024.